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Abstract
Objectives—Small intestinal neuroendocrine tumors (SI-NETs) are often detected after they 
have become metastatic. Using a novel protein array, we identified pathways important in SI-NET 
metastasis development in surgically resected patients.
Methods—Paired primary tumors and liver metastases from 25 patients undergoing surgical 
resection for metastatic SI-NETs were harvested. Extracted proteins were separated by SDS gel, 
and multiplex immunoblots were performed with 136 antibodies. Significant Analysis of 
Microarray was used to select for differentially expressed proteins. A tissue microarray was 
constructed from 27 archived specimens and stained by immunohistochemistry.
Results—Comparing primary SI-NETs to matched normal small bowel mucosa, 9 proteins were 
upregulated and Cyclin E was down-regulated. SI-NET liver metastases demonstrated up-
regulation of P-ERK and p27 but down-regulation of CDK2 and CDC25B. When comparing 
primary SI-NET with their paired liver metastases, cyclin E demonstrated a significant up-
regulation in the liver metastasis. Tissue microarray demonstrated higher p38 expression and 
lower Cdc 25b expression in SI-NETs vs liver metastases and confirmed higher expression of p27 
in liver metastases vs normal liver.
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Conclusions—Few studies have compared protein expression in paired primary and metastatic 
SI-NETs. Our findings reveal changes in a limited number of proteins, suggesting these may be 
targets for therapy.
Keywords
carcinoid; neuroendocrine; small bowel; liver metastasis; proteomics
Introduction
The prevalence and incidence of small intestinal neuroendocrine tumors (SI-NETs) is on the 
rise.[1, 2] Often presenting late with advanced disease, patients frequently die of their liver 
metastases. Limited information is currently available regarding the pathways important in 
the development of metastatic disease. In addition, the biologic behavior of SI-NETs is quite 
heterogeneous, making outcomes difficult to predict. For this reason, it would be helpful to 
identify biomarkers that could help to clarify prognosis or to predict response to therapy.
Currently, there are few known clinical, biochemical, and pathologic biomarkers that may 
help to prognosticate patients. Carcinoid syndrome and carcinoid heart disease are markers 
of advanced disease and predict poor prognosis. The biomarker chromogranin A is often 
helpful in diagnosis and surveillance of patients with neuroendocrine tumors, but is also 
falsely elevated by proton pump inhibition.[3–8] Pathologic features such as Ki67 or mitotic 
indices provide important but limited information in prediction of prognosis.[9, 10]
Most previous studies on molecular alterations in NET development, proliferation, and 
metastasis have focused on NETs from primary sites other than small bowel. The 
importance of the mTOR (mammalian target of rapamycin) pathway in NET pathogenesis 
has been demonstrated in multiple studies, and is confirmed by clinical trials demonstrating 
the efficacy of mTOR inhibitors in patients with pancreatic NETS.[11–14] Other groups 
have similarly shown the importance of the phosphatidylinositol-3-kinase (PI3K)-AKT 
pathway in tumor cell growth and angiogenesis in pancreatic NET cell lines, as well as in 
human clinical trials.[15–17]
We have developed and applied a protein array entitled Protein Pathway Array to study 
tumor biology in a variety of tumor types.[18, 19] Rather than being a nonspecific survey of 
proteins, this array encompasses proteins and phosphoproteins known to participate in well 
characterized biologic pathways important for cancer development (Table 1). This array 
permits an analysis of whether such proteins are up- or down-regulated. The aim of our 
study was to identify potential proteomic differences between primary SI-NETs and their 
liver metastases and to elucidate pathways important in metastasis development.
Methods
Tissue Specimens and Patient Data
Under an IRB-approved protocol, we retrieved tissue from surgically obtained specimens of 
SI-NETs and their liver metastases from the prospective Mount Sinai Tissue Bank. Fresh 
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frozen specimens from primary and metastatic sites were collected. Adjacent normal small 
intestine and normal liver specimens were also harvested.
Protein Pathway Array Analysis
Proteins were extracted, separated on an SDS gel and blotted on a multichannel manifold 
with 136 antibodies as described elsewhere (Table 1).[18, 19] The correct bands were 
identified and band densities were determined using BioRad Image system. Significant 
Analysis of Microarray (SAM) (http://www-stat.stanford.edu/~tibs/SAM/) was used to 
select the proteins differentially expressed between different groups. Unsupervised 
hierarchical clustering analysis was performed using BRB Array Tools software v.3.3.0 
(htt://linus.nci.nih.gov/BRB-ArrayTools.html).
Tissue Microarray Analysis
We created a tissue microarray with formalin-fixed paraffin-embedded SI-NETs retrieved 
from the Department of Pathology archives between 1998 and 2010. Formalin-fixed 
paraffin-embedded tissue from 27 specimens were processed with a manual tissue arrayer 
(Advanced Tissue Arrayer ATA100, Chemicon International, Temecula, CA) using 1-mm 
diameter cores in triplicate for tumors and for normal tissue sections. One H&E-stained 
section for each tissue microarray was prepared for histological confirmation of the tissue 
sections. 25 specimens had both primary and matched liver tumors.
Four-micrometer-thick histology sections were cut, and immunohistochemical staining was 
performed.17 Antibodies for p38 (1:50 dilution), XIAP (1:200), p27 (1:200), cyclin E 
(1:200), Cdc25b (1:50), Stat 3 (1:50), and Cdk4 (1:200) were used. Corresponding negative 
controls were incubated in the absence of primary antibody. Antibodies specific for NETs, 
such as chromogranin A, synaptophysin, and neuron-specific enolase were included in the 
panel as positive controls. A single pathologist (S.W.) examined the immunohistochemical 
expression profile of the antigens based on their staining intensity and localization pattern 
(i.e. cell membrane, cytoplasmic or nuclear). Both the extent of distribution and intensity of 
immunopositivity were recorded for the membrane and cytoplasmic immunostaining, with 
intensity grading ranging from 0 to 3 and the distribution extent of staining from 0% to 
100%. The final staining score (range = 0–300) was obtained by multiplying both scores. 
For nuclear immunostaining, the percentage of positive nuclei in 200 cells was calculated.
Results
Identification of differentially expressed proteins using Protein Pathway Array
Nine pairs of SI-NET and liver metastasis tissues were obtained from the Mount Sinai 
Tissue Bank. Of the 136 proteins analyzed, 52 proteins were expressed in these samples 
(Table 1). 9 proteins were up-regulated in primary SI-NETs compared with matched normal 
small bowel mucosa (Table 2). These included p-PDK1, PTEN, cdk4, MetRS, p27, XIAP, 
p38, Stat3, and alpha-tubulin. The degree of overexpression ranged from 3.4- to 21.5-fold in 
SI-NETs as compared to normal small intestinal tissue. Cyclin E was markedly 
downregulated in primary SI-NET tissue as compared to normal small bowel mucosa.
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Compared to normal liver tissue, SI-NET liver metastases demonstrated up-regulation of P-
ERK and p27 but down-regulation of CDK2 and CDC25B.
When comparing primary SI-NET with their paired liver metastases, cyclin E was the only 
protein to demonstrate differential expression; there was significant upregulation in the liver 
metastasis as compared to the primary lesion.
Validation using Tissue Microarray
To validate the PPA results, we selected several proteins to assess their expression on a 
TMA (Table 3). We chose proteins where there was more than two-fold change in 
expression between cancer and normal tissue based on PPA and where antibodies were 
available for Immunohistochemistry assay. We tested p38, XIAP, p27, cyclin E, Cdc25b, 
Stat3, and Cdk4 in our TMA.
In comparing primary SI-NETs and normal small bowel, TMA demonstrated statistically 
significant upregulation of cytoplasmic p38 MAP kinase, confirming the findings of the 
Protein Pathway Array (Figure 1, Table 2). TMA also demonstrated statistically significant 
downregulation of nuclear Cdc25B and Cdk4. The finding of the downregulation of Cdk4 is 
different from the findings of the Protein Pathway Array, which found upregulation of Cdk4 
in the SI-NET as compared to normal small bowel.
Compared to normal liver tissue, SI-NET liver metastases demonstrated statistically 
significant upregulation of p27, confirming the findings of the Protein Pathway Array. TMA 
also demonstrated statistically significant upregulation of p38, Cdk4, and Cyclin E. SI-NETs 
liver metastases also revealed downregulation of Cdc25B.
In comparison of SI-NETs and their liver metastases, TMA demonstrated higher p38 
expression and lower Cdc 25b expression in SI-NETs vs liver metastases (Figure 1 and 
Table 2).
Discussion
Small intestinal NETs have heterogeneous behavior that often presents clinical challenges. 
Because deaths due to SI-NETs are usually caused by metastatic disease, it is important to 
understand important pathways in tumor growth and metastasis development.
TMA confirmed some, but not all, specific PPA findings. Both PPA and TMA confirmed 
statistically significant up-regulation of cytoplasmic p38 in primary SI-NETs, as compared 
to normal small bowel. PPA and TMA also confirmed up-regulation of p27 in liver 
metastases compared to normal liver.
In some instances, TMA results were different from PPA findings, or elicited new findings. 
For instance, TMA demonstrated Cdk4 down-regulation in primary SI-NETs as compared to 
normal small bowel; this contrasted with PPA, which showed up-regulation of Cdk4 in SI-
NET as compared to normal small bowel. TMA alone demonstrated significant up-
regulation of p38, Cdk4, and Cyclin E and down-regulation of Cdc25B in liver metastases 
compared to normal liver. TMA alone also demonstrate higher p38 expression and lower 
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Cdc25b expression in SI-NETs as compared to liver metastases. Cdc25b plays an important 
role in the initial activation of the cell cycle, allowing mitosis to occur. Cdc25b has been 
found to be overexpressed in many neoplasms, including breast, thyroid, laryngeal, 
esophageal, gastric, and other cancers.[20] Overexpression may be associated with poor 
prognosis and high grade tumors.[20]
Our data demonstrated increased p27 expression in SI-NETs hepatic metastases compared to 
adjacent normal liver tissue. P27 is a member of the kinase inhibitor protein (KIP) family, 
with a negative effect on cyclin E/CDK2 and cyclin A/CDK2 and a positive effect on cyclin 
D/CDK complexes. A loss of p27 seems to have prognostic potential in breast, lung, colon, 
ovary, and prostate carcinomas.[21]
Our data also demonstrated increased p38 in primary SI-NETs as compared to normal small 
bowel. P38 catalyzes activation of other downstream kinases in cell-cell signaling.[22]
A strength of our study is that we analyzed primary and metastatic tissues from the same 
patients, as well as adjacent normal small intestine and liver. Previous studies have focused 
mainly on pancreatic NETs or a heterogeneous population of gastroenteropancreatic NETs, 
and analyzed a group of primary tumors that were not necessarily linked to metastases from 
the same patients.[23, 24] In addition, we applied a protein pathway approach that allowed 
us to identify pathways that are well known to play a role in tumor cell biology. By 
designing TMAs, we were able to confirm some of the findings of the PPA using an 
independent set of tumor tissues. The advantage of analyzing proteins and phosphoproteins 
is that we obtain a better understanding of the post-translational processing of DNA or RNA 
(used in other studies) which should provide a closer approximation of pathways that are 
indeed active in these tumors.
Despite this, our study does have some limitations. Because it is difficult to obtain tissue 
from synchronous primary and liver metastases of patients with SI-NETs, our sample size is 
limited. In addition, some of the markers that emerged as being either up- or down-regulated 
by PPA were not confirmed by TMA, which has been observed in our previous study.[25] It 
is probably due to the fact that IHC can determine the localization while PPA measures total 
protein, suggesting that these methods are complementary to each other.
Our study found that after analyzing many proteins involved in different cancer biology 
pathways, the proteins that seemed to be most important were those involved in cell cycle 
and proliferation. This confirms the importance of the mitotic index as an important 
component of how we predict tumor aggressiveness in SI-NETs. Future studies are needed 
to determine whether other pathways for which therapeutic agents are already developed, 
such as MAPK or others, might enhance our ability to treat SI-NETs or possibly predict 
clinical outcome.
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Figure 1. 
Immunohistochemical stain for p38 shows increased nuclear and cytoplasmic expression in 
a primary small intestinal NET (A) compared with the metastatic liver tumor (B) from the 
same patient (magnification X 400).
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Table 1
Selected proteins/phosphoproteins used in Protein Pathway Array
Angiogenesis: FGF, EPO, VEGF, VEGFR, NRP-1, Ang1, PDGF, PDGFR, TGF-beta, TGF-beta Receptor, Endoglin, VE-cadherin, CD31, 
NOS, COX-2, Id1/Id3, AC133, Angiopoietin, Laminin, Stabilin, Neuropilin, KDR, FLT1, IL8, Prokineticin, TNF alpha, IFN, IL6, COX1, 
MMP2, MMP9
Apoptosis/Autophagy: Bax, FAS, BAD, BCL2, BIK, BID, BAK, cleaved Caspase 3, cleaved Casepase 7, cleaved Caspase 8, cleaved Caspase 
9, TRAF, FADD, TRADD, p53, CD27, BRAF, PARP, XIAP, NFKB, IKB, TAK1, RIP1, Bcl-xL, FLIP, Smac, Cytochrome C, Apaf-1, LC-3I, 
LC-3II, Raptor, VPS15, Beclin1, TNF
Cell signaling: ERK1/2, p-ERK1/2 (Thr202/Tyr204), Akt, p-AKT (Ser473), HGF, HGFR, pHGFR (Y1234/Y1235), IGF, IGFR, TGF, TGFR, 
Notch 4, Notch 1, p38, p-p38 (Thr180/Tyr182), JNK, p-JNK (Thr183/Tyr185), FGFR, p-FGFR (Tyr653/654), VEGFR, p-VEGFR (Tyr951), 
PKC, p-PKCalpha (Ser657), p-PKCalpha/beta (Thr638/641), PTEN, p-PTEN (Ser380), PI3K, Ras, Raf, EGFR, p-EGFR (Tyr1068), p-EGFR 
(Tyr1148), p-EGFR (Tyr1173), Her2, p-Her2 (Tyr1221/1222), PDK1, p-PDK1 (Ser241), mTor, p-mTor (Ser2448), HSP90, NF-kB, IKB, c-Kit, 
c-Kit (Tyr719), PDGFR, GSK3, beta-catenin, p-beta-catenin (Ser33/37/Thr41), stat3, p-stat3 (Ser727), stat5, p-stat5 (Tyr694), smad, p-smad 
(Ser463/465), CREB, p-CREB (Ser133)
Cell Growth/Cell Proliferation: Rb, P21, P27, P15, P16, P18, P19, CHK1, CHK2, DP-1, MDM2, BRCA1, BRCA2, GADD45, 14-3-3, Myt1, 
IL18,
Cell cycle: CDK2, CDK4, CDK6, CDC2p34, CDC25A, CDC25B, CDC25C, CyclinA, Cyclin B, Cyclin D, Cyclin E, Rb, CyclinA, Cyclin B, 
Cyclin D, Cyclin E, CDK7
DNA repair: 53BP1, Ape1, ATM, ATR, BLM, Brg1, CK1, CK2, REDD1, Claspin, ERCC1, ERCC2, P53, Rad1, Rad9, Rad50, Rad51, Rad52, 
Mre11, MSH2, XRCC1
Epithelial-to-mesenchymal transition/Adhesion: CD44, ICAM1, VCAM1, E-Cadherin, Collagen, ECM1, HAS1, Catenin, Integrin, Laminin, 
MMP1, MMP10, Selectin E, Selectin L, Thrombospondin,
Invasion/metastasis: uPA, uPAR, NF-kappaB, AP-1, MMP1, MMP2, MMP9, MMP13, CDH1, CDH2, E-cadherin, N-cadherin, ICAM-1, 
laminin-5, CD44, osteopontin, VEGF, Connexin 43 (Cx43), Slit2, Robo1, Cas, NM23, MKK4, CCR7, CXCR4
Transcription factor: AR, MYC, CEBF, DR1, E2F, EGR1, ELK1, ETS, FOXA2, FOXO1, ESR1, FOS, GATA, Jun, JunB, JunD, MYB, 
STAT, TBP, SMAD, PPAR, RB1, REL, E2F1, ER, PR
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Table 2
Differentially expressed proteins in SI-NET primary and liver metastases as determined by PPA
A. SI-NET primary vs normal small intestine
Protein Ratio: Tumor/Normal (fold change) SAM (q%)
p-PDK1 +3.41 4.44
PTEN +21.47 4.44
Cdk4 +8.53 0
MetRS +8.53 0
P27 +11.95 0
XIAP +9.75 0
P38 +9.66 0
Stat 3 +10.38 0
Alpha-tubulin +11.90 0
Cyclin E −6.67 6.67
B. SI-NET liver metastasis vs normal liver
p-ERK +5.27 0
P27 +9.61 0
Cdk2 −1.78 0
Cdc25B −50.00 0
C. SI-NET liver metastasis vs SI-NET primary
Cyclin E +3.48 0
SI-NET: Small intestinal neuroendocrine tumor; PPA: Protein Pathway Array SAM: Significant Analysis of Microarray
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Table 3
Protein expression patterns determined by TMA
A. SI-NET primary vs normal small bowel
Protein Number (%) in SI-NET Number (%) in Normal SI p
P38 nuclear 20/27 (74.1) 17/19 (89.5) 0.27
P38 cytoplasmic 18/27 (66.7) 2/19 (10.5) 0.0002
Cdc25b nuclear 10/26 (38.4) 19/19 (100) <0.0001
Cdc25b cytoplasmic 5/26 (10.2) 8/19 (42.1) 0.11
P27 nuclear 22/27 (81.5) 15/19 (78.9) 1.00
Cyclin E 27/27 (100) 19/19 (100) 1.00
Cdk4 12/27 (44.4) 19/19 (100) <0.0001
B. SI-NET liver metastasis vs normal liver
Protein Number (%) in Liver Met Number (%) in Normal Liver p
P38 nuclear 8/25 (32.0) 1/21 (4.8) 0.03
P38 cytoplasmic 7/25 (28.0) 0/21 (0) 0.01
Cdc25b cytoplasmic 12/25 (48) 21/21 (100) 0.03
P27 nuclear 20/25 (80) 4/21 (19) <0.0001
Cyclin E 25/25 (100) 13/21 (62) 0.0008
Cdk4 12/25 (48) 0/21 (0) 0.0001
C. SI-NET vs SI-NET liver metastasis
Protein Number (%) in SI-NET Number (%) in Liver Met p
P38 nuclear 20/27 (74.1) 8/25 (32) 0.0002
P38 cytoplasmic 18/27 (66.7) 7/25 (28) 0.0005
Cdc25b cytoplasmic 5/26 (19.2) 12/25 (48) 0.03
P27 nuclear 22/27 (81.5) 20/25 (80) 1.00
Cyclin E 27/27 (100) 25/25 (100) 1.00
Cdk4 12/27 (44.4) 12/25 (48) 1.00
TMA: Tissue Microarray; SI-NET: Small intestinal neuroendocrine tumor; SI: small intestine
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